New combo therapy targets hard-to-treat head and neck cancers
NCT ID NCT05838729
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This study tests a new drug (RiMO-301) given with targeted radiation and an immunotherapy drug (a PD-1 inhibitor) for people with advanced head and neck cancer that cannot be removed by surgery or has spread. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 16 participants will receive the treatment to evaluate its effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.